Crowdonomics
All companies
Titomirov Vodka logo

Titomirov Vodka

Operating

Titomirov Vodka LLC

Food & Beverage · Jupiter, FL

Post-money valuation ⓘ
$39.5M
As of Oct 2018 · from Reg CF Offering (2018) · pre-money + amount raised, not a traded price
Total raised
$68,392
Across 1 round since 2018
Latest share price
$2.00
Reg CF · Common Stock · May 2018 offering price

Financials

FY2016–FY2017 · from SEC filings · hover any figure for its source
$30K
−$309K
2016
$171K
−$484K
2017
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2016 unaudited*
FY2017 unaudited*
Income statement
Revenue
$30,450
$171,243
Cost of goods sold
$4,720
$50,922
Gross margin
84%
70%
Net income
-$309,270
-$483,679
Taxes paid
$0
$0
Balance sheet
Cash
$20,000
$90,000
Accounts receivable
$15,000
$45,000
Total assets
$6,813,530
$7,021,266
Short-term debt
$199,345
$109,137
Long-term debt
$0
$0
Total liabilities
$199,345
$109,137
Other
Headcount
—
5

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$39.4M
pre-money
Reg CF · Common · May 2018

Blue bars are the pre-money valuation the company stated for a priced round.

Fundraising history

Raised $68.4K / $107KInvestors 60Post-money $39.5M

Team

2 people
Alexander TitomirovFounder
Founder & CEO

Alex has been founder, CEO, & Director of Titomirov Vodka since 2014. Also a successful biotech CEO, Alexander Titomirov founded one of the first bioinformatics companies - InforMax [NASDAQ, INMX] and brought it public ($1 billion market cap) with “the best biotech IPO” [Washington Post, 2000] in the State of Maryland. Dr. Titomirov and his company InforMax Inc. were developers of the best medical search engine www.PubMed.org as well as huge contributors in developing the National Center for Biotechnology Information (NCBI) through contract with InforMax Inc. which lasted for over 10 years. Titomirov was a founder of several pioneering technologies in the field of cancer treatment at the Russian Academy of Sciences. He discovered a bacterial DHFR genetic effect that prolonged the lifespan in irradiated mice, and he was one of the original authors of stable gene transformation of skin cells in vivo using the pioneering technology of “shot gun” with tungsten micro projectiles. Titomirov was invited to come to work in the United States by James Watson – a Nobel Prize winner and a pioneer in discovering the structure of DNA. He worked at the National Institutes of Health as well as in a small pharmaceutical company before starting his own company InforMax, Inc. in 1990. Titomirov has pioneered an expert system based on modeling of the drug discovery process. InforMax products are currently sold to over 65,000 pharma and biotech companies worldwide. InforMax was acquired by Invitrogen, a major bio-science company with $1.2 billion in annual revenues, headquartered in Carlsbad, California. In addition, Titomirov was one of the principal developers of the software infrastructure for the Human Genome Project, founded by James Watson. Titomirov was a major contributor to the Genomics Approach of drug discovery – which is demonstrated to be one of the main accelerators of drug discovery process. Titomirov earned his Ph.D. in 1986 at the Institute of Cytology at the Russian Academy of Sciences in St. Petersburg, Russia. Dr. Titomirov pioneered the field of transforming animal cells with foreign DNA which had led to development of human DNA vaccines and was a major contribution to human genetics with more than 50 books[1] written based on Dr. Titomirov's original article

Jonathan Ribolini
Global Sales Manager

Jonathan Ribolini is an experienced sales manager with the global reach in operations Trained in Monaco 🇲🇨Jonathan has helped our brand development in Europe and now will oversee global sales. He’s fluent in French and English. Jonathan has run a successful beverage and food operations in Monaco.

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Delinquent

Filed 0 of 8 annual reports (FY2018–FY2025)

Missing: 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025

60 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-UOct 3, 20180001665160-18-001025
    EDGAR
  • Form C/AJul 24, 20180001665160-18-000721
    EDGAR
  • Form CMay 4, 20180001665160-18-000420
    EDGAR
Source: SEC EDGARCIK 0001736164FLShare price $2.00Last synced Aug 17, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.